By a News Reporter-Staff News Editor at Pharma Business Week -- Ophthotech Corporation (Nasdaq:OPHT) announced the election of Ian F. Smith, Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, to its Board of Directors, effective immediately. Mr. Smith has also been elected the Chair of the Ophthotech Audit Committee (see also Pharmaceutical Companies).
Mr. Smith has more than 15 years of experience in the biopharmaceutical industry; he currently serves as Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, a global biotechnology company that discovers, develops and commercializes innovative medicines. Mr. Smith holds responsibility for core functions at Vertex, including Finance and Accounting, Investor Relations, Corporate and Business Development, Global Information Systems and Worldwide Operations, and he is a member of the Executive Team. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm.
"We are excited to have attracted someone of Ian's stature to join our Board of Directors," stated David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board of Ophthotech. "Ian's outstanding and proven track record at Vertex and his financial, operations and commercial expertise will be beneficial to Ophthotech's future growth."
"Ophthotech is positioned to build on the strong momentum that it has established in the retina community," stated Mr. Ian F. Smith. "I am delighted to be a part of this passionate and committed team whose goal is to develop science-driven breakthrough therapies. I look forward to working closely with the other board members and the management team."
Keywords for this news article include: Vertex Pharmaceuticals, Investment and Finance, Ophthotech Corporation, Biotechnology Companies, Biopharmaceutical Companies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC
(c) 2016 NewsRx LLC, source Health Newsletters